Paper17523848
Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR and 5 others. Radiat Res, 2007. Cited by 55 papers, by iCite.
Cite this record
ConductScience Library. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Papers, record 17523848. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17523848
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bystander Effect | Major topic |
| Cell Hypoxia | Major topic |
| Cell Survival | Major topic |
| Lung Neoplasms | Major topic |
| Nitrogen Mustard Compounds | Major topic |
| Antineoplastic Agents, Alkylating | |
| Cell Line, Tumor | |
| Dose-Response Relationship, Drug | |
| Dose-Response Relationship, Radiation | |
| Feasibility Studies | |
| Humans | |
| Oxidation-Reduction | |
| Prodrugs | |
| Radiation Dosage | |
| Radiation Tolerance |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CA82566 | NCI NIH HHS | United States | P01CA082566 | PubMed and NIH |
Source NIH RePORTER
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 55 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41476118 | PISTOL MRI allows noninvasive assessment of changes in tumor oxygenation post hypoxia targeted therapy. | Sci Rep | 2025 | https://conductscience.org/library/papers/41476118 | PubMed |
| 39750141 | Versatile Stimuli-Responsive Controlled Release of Pinanediol-Caged Boronic Esters for Spatiotemporal and Nitroreductase-Selective Glucose Bioimaging. | ACS Sens | 2025 | https://conductscience.org/library/papers/39750141 | PubMed |
| 34625504 | Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506. | Mol Cancer Ther | 2021 | https://conductscience.org/library/papers/34625504 | PubMed |
| 34326502 | Therapeutic targeting of the hypoxic tumour microenvironment. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/34326502 | PubMed |
| 34245333 | Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug. | Cancer Chemother Pharmacol | 2021 | https://conductscience.org/library/papers/34245333 | PubMed |
| 33897898 | Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy. | Theranostics | 2021 | https://conductscience.org/library/papers/33897898 | PubMed |
| 33558701 | Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. | Cancer Gene Ther | 2022 | https://conductscience.org/library/papers/33558701 | PubMed |
| 33105798 | Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity. | Molecules | 2020 | https://conductscience.org/library/papers/33105798 | PubMed |
| 32929365 | E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications. | Theranostics | 2020 | https://conductscience.org/library/papers/32929365 | PubMed |
| 31337055 | Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models. | Cells | 2019 | https://conductscience.org/library/papers/31337055 | PubMed |
| 30734002 | Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. | Clin Transl Radiat Oncol | 2019 | https://conductscience.org/library/papers/30734002 | PubMed |
| 30591421 | An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect. | Neoplasia | 2019 | https://conductscience.org/library/papers/30591421 | PubMed |
| 30575832 | Hypoxia-targeted drug delivery. | Chem Soc Rev | 2019 | https://conductscience.org/library/papers/30575832 | PubMed |
| 30279659 | Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/30279659 | PubMed |
| 29423880 | Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue. | Bull Math Biol | 2019 | https://conductscience.org/library/papers/29423880 | PubMed |
| 27070712 | Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. | Br J Cancer | 2016 | https://conductscience.org/library/papers/27070712 | PubMed |
| 24409417 | Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling. | Front Oncol | 2013 | https://conductscience.org/library/papers/24409417 | PubMed |
| 24109591 | The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. | Front Oncol | 2013 | https://conductscience.org/library/papers/24109591 | PubMed |
| 23758947 | Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy. | Mol Cancer | 2013 | https://conductscience.org/library/papers/23758947 | PubMed |
| 21836632 | Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo. | Cancer Gene Ther | 2011 | https://conductscience.org/library/papers/21836632 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| POR | 5447 | PubTator's text mining | https://conductscience.org/library/genes/5447 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17523848
GET https://conductscience.org/api/papers/v1/17523848/cited_by?page=2